Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.21
ACUR's Cash to Debt is ranked lower than
59% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. ACUR: 1.21 )
Ranked among companies with meaningful Cash to Debt only.
ACUR' s 10-Year Cash to Debt Range
Min: 0  Med: 0.16 Max: No Debt
Current: 1.21
Equity to Asset 0.28
ACUR's Equity to Asset is ranked lower than
89% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACUR: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
ACUR' s 10-Year Equity to Asset Range
Min: -7.86  Med: -0.61 Max: 0.97
Current: 0.28
-7.86
0.97
F-Score: 5
Z-Score: -32.36
M-Score: 23.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -93.96
ACUR's Operating margin (%) is ranked lower than
90% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. ACUR: -93.96 )
Ranked among companies with meaningful Operating margin (%) only.
ACUR' s 10-Year Operating margin (%) Range
Min: -11455.28  Med: -144.32 Max: 51.47
Current: -93.96
-11455.28
51.47
Net-margin (%) -110.23
ACUR's Net-margin (%) is ranked lower than
90% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. ACUR: -110.23 )
Ranked among companies with meaningful Net-margin (%) only.
ACUR' s 10-Year Net-margin (%) Range
Min: -11301.63  Med: -164.84 Max: 50.74
Current: -110.23
-11301.63
50.74
ROE (%) -104.41
ACUR's ROE (%) is ranked lower than
94% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. ACUR: -104.41 )
Ranked among companies with meaningful ROE (%) only.
ACUR' s 10-Year ROE (%) Range
Min: -114.99  Med: -46.85 Max: 51.89
Current: -104.41
-114.99
51.89
ROA (%) -38.95
ACUR's ROA (%) is ranked lower than
89% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. ACUR: -38.95 )
Ranked among companies with meaningful ROA (%) only.
ACUR' s 10-Year ROA (%) Range
Min: -1207.97  Med: -88.41 Max: 33.14
Current: -38.95
-1207.97
33.14
ROC (Joel Greenblatt) (%) -588.13
ACUR's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. ACUR: -588.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1226.13  Med: -445.16 Max: 1628.06
Current: -588.13
-1226.13
1628.06
Revenue Growth (3Y)(%) -66.50
ACUR's Revenue Growth (3Y)(%) is ranked lower than
98% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ACUR: -66.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACUR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -42.10 Max: 27.3
Current: -66.5
0
27.3
» ACUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ACUR Guru Trades in Q3 2014

Jim Simons 44,900 sh (+253.54%)
» More
Q4 2014

ACUR Guru Trades in Q4 2014

Jim Simons 91,500 sh (+103.79%)
» More
Q1 2015

ACUR Guru Trades in Q1 2015

Jim Simons 128,900 sh (+40.87%)
» More
Q2 2015

ACUR Guru Trades in Q2 2015

Jim Simons 177,700 sh (+37.86%)
» More
» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.67
ACUR's P/B is ranked lower than
79% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. ACUR: 6.67 )
Ranked among companies with meaningful P/B only.
ACUR' s 10-Year P/B Range
Min: 1.6  Med: 5.05 Max: 15.93
Current: 6.67
1.6
15.93
P/S 4.56
ACUR's P/S is ranked lower than
62% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. ACUR: 4.56 )
Ranked among companies with meaningful P/S only.
ACUR' s 10-Year P/S Range
Min: 2.8  Med: 36.34 Max: 990
Current: 4.56
2.8
990
EV-to-EBIT -5.51
ACUR's EV-to-EBIT is ranked lower than
181% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. ACUR: -5.51 )
Ranked among companies with meaningful EV-to-EBIT only.
ACUR' s 10-Year EV-to-EBIT Range
Min: -45.3  Med: -2.10 Max: 63
Current: -5.51
-45.3
63
Current Ratio 3.10
ACUR's Current Ratio is ranked higher than
63% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ACUR: 3.10 )
Ranked among companies with meaningful Current Ratio only.
ACUR' s 10-Year Current Ratio Range
Min: 0.02  Med: 1.08 Max: 68.17
Current: 3.1
0.02
68.17
Quick Ratio 3.04
ACUR's Quick Ratio is ranked higher than
71% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ACUR: 3.04 )
Ranked among companies with meaningful Quick Ratio only.
ACUR' s 10-Year Quick Ratio Range
Min: 0.01  Med: 0.84 Max: 68.17
Current: 3.04
0.01
68.17
Days Inventory 211.82
ACUR's Days Inventory is ranked lower than
86% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. ACUR: 211.82 )
Ranked among companies with meaningful Days Inventory only.
ACUR' s 10-Year Days Inventory Range
Min: 39.68  Med: 83.92 Max: 752.41
Current: 211.82
39.68
752.41
Days Sales Outstanding 6.24
ACUR's Days Sales Outstanding is ranked higher than
95% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. ACUR: 6.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACUR' s 10-Year Days Sales Outstanding Range
Min: 2.73  Med: 32.35 Max: 575.69
Current: 6.24
2.73
575.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 287.00
ACUR's Price/Net Cash is ranked lower than
99% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.86 vs. ACUR: 287.00 )
Ranked among companies with meaningful Price/Net Cash only.
ACUR' s 10-Year Price/Net Cash Range
Min: 2.79  Med: 7.09 Max: 493.5
Current: 287
2.79
493.5
Price/Net Current Asset Value 23.92
ACUR's Price/Net Current Asset Value is ranked lower than
87% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. ACUR: 23.92 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACUR' s 10-Year Price/Net Current Asset Value Range
Min: 2.74  Med: 6.98 Max: 90.32
Current: 23.92
2.74
90.32
Price/Tangible Book 11.48
ACUR's Price/Tangible Book is ranked lower than
84% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. ACUR: 11.48 )
Ranked among companies with meaningful Price/Tangible Book only.
ACUR' s 10-Year Price/Tangible Book Range
Min: 2.64  Med: 6.62 Max: 79.25
Current: 11.48
2.64
79.25
Price/Median PS Value 0.13
ACUR's Price/Median PS Value is ranked higher than
98% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. ACUR: 0.13 )
Ranked among companies with meaningful Price/Median PS Value only.
ACUR' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 0.16 Max: 26.39
Current: 0.13
0.01
26.39
Earnings Yield (Greenblatt) (%) -18.10
ACUR's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ACUR: -18.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACUR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.6  Med: 8.40 Max: 48.2
Current: -18.1
1.6
48.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 8 5 14
EPS($) -0.17 -0.21 -0.05
EPS without NRI($) -0.17 -0.21 -0.05

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HD4B.Germany,
Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed its Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
What to Watch for: November 3-7 Nov 04 2014 
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints Oct 15 2014 
Acura Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 02 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 29 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 26 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 30 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) May 01 2009 
American Honda Reports 2008 Annual and December Monthly Sales Jan 05 2009 
Acura Announces December and 2008 Year-End Sales Results Jan 05 2009 

More From Other Websites
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Material Modification to Rights of Security Holders,... Aug 27 2015
Acura Pharmaceuticals Announces 1-for-5 Reverse Stock Split Aug 24 2015
Acura Pharmaceuticals approves one-for-five reverse stock split Aug 24 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Aug 24 2015
Acura Pharmaceuticals Announces 1-for-5 Reverse Stock Split Aug 24 2015
ACURA PHARMACEUTICALS, INC Financials Aug 08 2015
Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results Aug 03 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 03 2015
Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results Aug 03 2015
Q4 2015 Acura Pharmaceuticals Inc Earnings Release - After Market Close Aug 03 2015
Acura Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call on August 4,... Jul 27 2015
Acura Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call on August 4,... Jul 27 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jul 01 2015
Acura Pharmaceuticals to Raise Approximately $7.6 Million From Institutional Healthcare Investors Jul 01 2015
Acura Pharmaceuticals to Raise Approximately $7.6 Million From Institutional Healthcare Investors Jul 01 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Termination of a Material Definitive Agreement Jun 30 2015
Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent... Jun 29 2015
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2015
Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent... Jun 29 2015
Acura Pharmaceuticals (ACUR) Stock Spikes on Development Deal with Bayer Healthcare Jun 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK